GlassScriptPhysician profile
Cari Callaway
NPI 1629562053
$5,338.96
in general payments reported to CMS, 2019-2025
19 companies · $1,252 in 2025
The $1,252 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $549 · 2022: $1,729 · 2023: $1,031 · 2024: $778 · 2025: $1,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,034 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,033.85 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,340.47 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $720.17 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $598.95 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $432.90 | 2023-2025 | Austedo Xr, Austedo, Uzedy |
| Otsuka America Pharmaceutical, INC. | $416.33 | 2021-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| E.R. Squibb & Sons, L.L.C. | $370.23 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $313.05 | 2021-2024 | Rexulti |
| Axsome Therapeutics, INC. | $263.78 | 2022-2025 | Auvelity |
| Alkermes, INC. | $219.49 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Supernus Pharmaceuticals, INC. | $166.88 | 2022-2025 | Qelbree, Qelbree |
| Corium, LLC | $122.67 | 2023-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $84.25 | 2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $79.67 | 2023-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $64.51 | 2022-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $47.59 | 2023-2024 | Quviviq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $45.08 | 2024 | |
| Sunovion Pharmaceuticals INC. | $23.92 | 2021 | |
| Avanir Pharmaceuticals, INC. | $16.14 | 2022 | |
| Noven Therapeutics, LLC | $12.88 | 2023 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cari Callaway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.